Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(2)
•••
Comment by toinv261on Oct 21, 2017 6:49pm
123 Views
Post# 26841269

RE:RE:RE:RE:RE:RE:RE:RE:Market Passion in the affirmative...NOT!

RE:RE:RE:RE:RE:RE:RE:RE:Market Passion in the affirmative...NOT!GV, the weather is stunning in Muskoka. I'm watching a remarkable sunset!

OK, I understand your calcs.

RE funding source I really hope that Don has been working on a counter-balancing deal and also a deal that makes strategic sense in terms of geography, strategic fit, scientific fit,etc. My fear is I believe Don has been working on some sort of deal for at least 13 months and he has not delivered. I hope I am wrong but I do not believe Don is the right guy at this stage of the company. I mean look what happened with the Hepa funding. I believe Don has himself trapped.

Then add to this the extended length of the trial and the uncertainty around the FA and it leads me to a great deal of concern.

I'm not selling my shares. There is no point in selling. I still believe in the science but the business side needs to be fixed. 

GLTA
Toinv
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities